TGFBR1 and neoplasm: To confirm the effect of the TβRI inhibitor, we evaluated the phosphorylation of Smad2 and Smad4, which are downstream targets of the receptor, by immunohistochemistry in tumor samples from allergic mice and allergic mice treated with the inhibitor.